Click on the button below to apply for this position.
Exciting pharmacology position at a successful biotech company focusing on unmet medical needs within oncology
Y-mAbs is a rapidly growing late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company has one approved drug (Danyelza; anti GD2 mAb, FDA approved), as well as a broad and advanced product pipeline, including pivotal-stage product candidates, as well as pre-clinical compounds which target both solid and hematologic tumor targets.
In the newly established position as Principal Scientist, you will be responsible for pre-clinical pharmacology programs including designing and conducting studies, primarily as CRO-based activities ensuring a strong link to the early clinical studies including pharmacokinetics and biomarkers.
You will join the Translational Medicine group covering all pharmacology, toxicology, target discovery, assay development and First in Human clinical protocols.
With direct report to Chief Scientific Officer, Global Head Translational Medicine.
Your main tasks are:
Your qualifications are exceptional technical and scientific skills to develop and implement pharmacology and strategies to advance the development of drug candidates from pre-clinical into clinical development focusing on large molecules including monoclonal antibodies, bispecific antibodies and radio-conjugated antibodies.
The preferred candidate has solid experience with in vivo and in vitro pharmacology model systems, preferably within the field of immunology or oncology, and an ability to integrate pre-clinical PK and PD data, for optimal target evaluation, design of the pre-clinical program and translation to the clinic. You should have an understanding of the overall process of drug development and the pharmaceutical R&D process and the ability to handle contributions to multiple pharmacology programs, simultaneously.
Experience with writing pharmacology regulatory submission documents is an advantage, and you have a demonstrated scientific acumen and mechanistic understanding of disease biology.
Finally, you can recognize, articulate and accept calculated risks to make informed decisions.
A PhD or equivalent degree in Pharmaceutical Sciences, Pharmacology, or relevant Biological Sciences with a minimum of 5 years of relevant experience (including postdoctoral studies) is required.
You can distill complex issues and clearly articulate solutions. You are a hands-on team player with the ability to demonstrate effectiveness and growth in a fast-paced and dynamic environment.
As a person, you are highly analytical, comfortable with numbers, and can act independently and have good presentation and communication skills. You have a highly developed ability to cooperate with multiple stakeholders in an international company, both internally and externally. You deliver on your promises, and you are detail-oriented while understanding and working within a larger framework.
Finally, you are able to integrate into a small, very competent team, who’s success is dependent on the positive and pro-active attitude and contribution of everyone. You have good collaboration skills, are open-minded and you have your own opinions, which you are not afraid to express. You also proactively take ownership for strategies/decisions.
Y-mAbs offers an exciting opportunity in a successful biotech company in which you will have a high degree of influence on your own job and gain experience with a diverse range of molecular biological modalities and disease targets. The position will allow you to create a sustainable footprint while developing professionally.
Travelling: 10 days per year (post COVID-19).
For more details about the job or the company, please contact CEO Jørn Duhn, Unique Human Capital on M: +45 21 75 19 25 or Senior Research Consultant Elisabeth Haun, Unique Human Capital on M: +45 28 90 33 88. All applications must be in English and are treated confidentially.